NCT02176356

Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 116 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 35 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

A study to evaluate patient satisfaction, aesthetic and psychological impact of combined treatment with BOTOX® Cosmetic (onabotulinumtoxinA), JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS XC, JUVÉDERM® VOLUMA® XC, and LATISSE® (bimatoprost ophthalmic solution).

Conditions

• Facial Rhytides
• Crow's Feet Lines
• Glabellar Lines
• Nasolabial Fold

Interventions

Type	Name	Description
BIOLOGICAL	onabotulinumtoxinA	onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
DRUG	bimatoprost ophthalmic solution 0.03%	bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
DEVICE	JUVÉDERM® ULTRA XC	JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
DEVICE	JUVÉDERM® ULTRA PLUS XC	JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
DEVICE	JUVÉDERM® VOLUMA® XC	JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.

Timeline

• Start date: 2014-06-30
• Primary completion: 2015-05-03
• Completion: 2015-05-03
• First posted: 2014-06-27
• Last updated: 2019-01-09
• Results posted: 2016-06-16

Locations

1 site across 1 country: United States